Medical Marijuana for IBS in Florida
Irritable bowel syndrome causing chronic abdominal pain and digestive disruption.
Medically reviewed by Bruce Stratt, MD
Board-Certified Physician · OMMU Certified · Boca Raton, FL
Overview
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder affecting an estimated 25–45 million Americans. It is characterized by recurrent abdominal pain and cramping associated with changes in bowel habits — either diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), or mixed (IBS-M). IBS significantly impacts quality of life and can keep sufferers virtually homebound during severe flare-ups, affecting work productivity, social activities, and mental health.
The exact cause of IBS remains incompletely understood, but it involves dysfunction in the gut-brain axis, visceral hypersensitivity (where the gut overreacts to normal stimuli), altered gut motility, low-grade mucosal inflammation, and potentially gut microbiome imbalances. Conventional treatments include dietary modifications (low-FODMAP diets), antispasmodics, laxatives or antidiarrheals, and low-dose antidepressants. Many patients find these approaches provide only partial symptom relief, and the unpredictable nature of flare-ups creates significant daily anxiety.
IBS qualifies for medical marijuana in Florida under the chronic pain or "comparable conditions" provision of Statute 381.986. The gastrointestinal tract contains one of the highest concentrations of endocannabinoid receptors in the body, making it highly responsive to cannabinoid therapy — and research is increasingly supporting this therapeutic approach.
How Medical Cannabis May Help
The gastrointestinal tract is richly populated with endocannabinoid receptors (both CB1 and CB2), and cannabinoid signaling plays a key role in regulating gut motility, visceral sensation, and intestinal inflammation. A randomized, placebo-controlled trial (Wong et al., Gastroenterology, 2011) demonstrated that dronabinol (a CB1 receptor agonist) reduced fasting colonic motility in patients with non-constipated IBS (IBS-D), providing direct clinical evidence for cannabinoid therapy in IBS. Interestingly, the study also found that genetic variations in the CB1 receptor gene influenced the magnitude of response — early evidence for personalized cannabinoid medicine. A proof-of-concept trial presented at the American College of Gastroenterology (2023) tested a CBD/CBG oral tincture in IBS patients and found a 44% reduction in pain scores within 14 days — from 6.6 at baseline to 3.7. Five of six patients experienced meaningful pain reduction. THC-containing formulations appear more effective than CBD alone for gut motility issues, as CB1 receptor activation on enteric neurons inhibits acetylcholine release, reducing peristaltic contractions and slowing transit — particularly beneficial for IBS-D. Cannabis also helps manage the secondary symptoms of IBS including poor appetite, nausea, and sleep disruption, as well as the anxiety that both triggers and accompanies IBS flare-ups. Dr. Stratt will assess your specific IBS subtype (IBS-D, IBS-C, or IBS-M) and symptom profile to recommend an appropriate treatment approach — the optimal formulation varies significantly between subtypes.
Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.
What to Bring to Your Appointment
Bring a valid Florida ID and gastroenterology records confirming IBS diagnosis, any colonoscopy or diagnostic test results, and a list of current medications.
Frequently Asked Questions
Related Articles
Patient Resources
Get Your Medical Marijuana Card for IBS
Schedule your evaluation with Dr. Stratt. Same-day state registry submissions for qualifying patients.